Boehringer Ingelheim taps Envisagenics AI in potential $1B-plus cancer-target deal on September 23, 2026 ADCs AI drug discovery Boehringer Ingelheim Envisagenics multispecific antibodies precision oncology RNA RNA Splicing Solid Neoplasm SpliceCore T-cell engagers +